Boston Scientific to purchase Elutia’s drug-eluting envelope business for $88M
Boston Scientific has agreed to acquire Elutia’s drug-eluting envelope business for $88 million. The cash transaction is expected to close in late 2025.
Elutia is the Maryland-based medtech company behind EluPro, a new biologic envelope specifically designed for patients with implantable pacemakers and defibrillators. The envelope’s walls are embedded with rifampin and minocycline, two antibiotics delivered to the patient for an extended period of time following implantation. It was designed to regenerate into a “protective pocket of the patient’s own tissue,” reducing the risk of infection or other complications. The U.S. Food and Drug Administration cleared EluPro in 2024. That approval also covered the use of EluPro when implanting noncardiac devices such as neurostimulators and neuromodulators.
Image courtesy of Elutia.
“EluPro has clearly demonstrated that our proprietary drug-eluting biologics platform works at scale,” Randy Mills, PhD, CEO of Elutia, said in a prepared statement. “With the successful launch of EluPro, seven national group purchasing organization contracts secured and more than 160 value analysis committee approvals, we have shown that we can develop, manufacture and commercialize these highly regulated breakthrough products, and that they are valued by physicians.”
According to Elutia, inking this deal helps it “eliminate outstanding debt, substantially resolve litigation from the company’s previously digested orthobiologics business and leave the company with a significantly reduced burn rate.” Going forward, Elutia’s primary goals will be the advancement of its NXT-41x technology within the breast reconstruction market and its SimpliDerm technology within the plastic surgery market.
Elutia was known as Aziyo Biologics until the company rebranded in 2023.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.